CA3218573A1 - Composes pour la degradation d'agregats d'alpha-synucleine et leurs utilisations - Google Patents

Composes pour la degradation d'agregats d'alpha-synucleine et leurs utilisations Download PDF

Info

Publication number
CA3218573A1
CA3218573A1 CA3218573A CA3218573A CA3218573A1 CA 3218573 A1 CA3218573 A1 CA 3218573A1 CA 3218573 A CA3218573 A CA 3218573A CA 3218573 A CA3218573 A CA 3218573A CA 3218573 A1 CA3218573 A1 CA 3218573A1
Authority
CA
Canada
Prior art keywords
alkyl
formula
substituted
compound
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3218573A
Other languages
English (en)
Inventor
Ming-Kuei Jang
Paul Tempest
Yih-Shyan Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aprinoia Therapeutics Ltd
Original Assignee
Aprinoia Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aprinoia Therapeutics Ltd filed Critical Aprinoia Therapeutics Ltd
Publication of CA3218573A1 publication Critical patent/CA3218573A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Treating Waste Gases (AREA)

Abstract

La présente invention concerne des composés comprenant une fraction de liaison à l'ubiquitine ligase E3 et une fraction de liaison à la protéine alpha-synucléine, destinés à être utilisés dans le traitement de maladies neurodégénératives, en particulier de synucléinopathies.
CA3218573A 2021-05-14 2021-05-14 Composes pour la degradation d'agregats d'alpha-synucleine et leurs utilisations Pending CA3218573A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2021/054167 WO2022238737A1 (fr) 2021-05-14 2021-05-14 Composés pour la dégradation d'agrégats d'alpha-synucléine et leurs utilisations

Publications (1)

Publication Number Publication Date
CA3218573A1 true CA3218573A1 (fr) 2022-11-17

Family

ID=76034924

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3218573A Pending CA3218573A1 (fr) 2021-05-14 2021-05-14 Composes pour la degradation d'agregats d'alpha-synucleine et leurs utilisations

Country Status (8)

Country Link
EP (1) EP4337259A1 (fr)
JP (1) JP2024517340A (fr)
KR (1) KR20240008335A (fr)
CN (1) CN117377496A (fr)
AU (1) AU2021444937A1 (fr)
CA (1) CA3218573A1 (fr)
TW (1) TW202304516A (fr)
WO (1) WO2022238737A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10300155B2 (en) * 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
WO2018102067A2 (fr) 2016-11-01 2018-06-07 Arvinas, Inc. Protacs ciblant la protéine tau et méthodes d'utilisation associées
ES2965049T3 (es) 2017-07-12 2024-04-10 Dana Farber Cancer Inst Inc Compuestos para la degradación de la proteína tau
AU2019265346B2 (en) 2018-05-09 2022-06-16 Aprinoia Therapeutics Limited Heteroaryl compounds and uses thereof
WO2020041331A1 (fr) * 2018-08-20 2020-02-27 Arvinas Operations, Inc. Composé chimère ciblant la protéolyse (protac) ayant une activité de liaison à l'ubiquitine ligase e3 et ciblant une protéine alpha-synucléine pour le traitement de maladies neurodégénératives

Also Published As

Publication number Publication date
AU2021444937A1 (en) 2023-11-30
EP4337259A1 (fr) 2024-03-20
JP2024517340A (ja) 2024-04-19
TW202304516A (zh) 2023-02-01
WO2022238737A1 (fr) 2022-11-17
KR20240008335A (ko) 2024-01-18
CN117377496A (zh) 2024-01-09

Similar Documents

Publication Publication Date Title
US11065231B2 (en) Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
AU2017222958B2 (en) Glycosidase inhibitors
AU2017222964B2 (en) Glycosidase inhibitors
EP2838898B1 (fr) Composés hétéro-bicycliques substitués, compositions et leurs applications médicinales
CA3095912A1 (fr) Ligands de cereblon et composes bifonctionnels les contenant
KR20190067923A (ko) 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
JP6851367B2 (ja) Ｉｒａｋ４阻害剤、及びその応用
US20160194311A1 (en) Substituted nicotinamide derivatives as kinase inhibitors
WO2006093247A1 (fr) NOUVEAU COMPOSÉ AMINOPYRIDINE AYANT UNE ACTIVITÉ D'INHIBITION DE LA Syk
EP1761530A1 (fr) Nouveaux derives de 5-aryl-1h-pyrrolo [2, 3b] pyridine-3-carboxamide ou d'acide 5-aryl-1h-pyrrolo [2, 3b] pyridine-3-carboxylique
CA2595157A1 (fr) Derives d'imidazole et de benzimidazole utiles en tant qu'antagonistes de l'histamine h3
CA3172387A1 (fr) Composes a base d'indazole et procedes d'utilisation associes
TW201333005A (zh) １,５－萘啶衍生物與含此之ｍｅｌｋ抑制劑
CA3074059A1 (fr) Derives de 2-azabicyclo[3.1.1]heptane et de 2-azabicyclo[3.2.1]octane substitues en tant qu'antagonistes du recepteur de l'orexine
CN112912142A (zh) 作为腺苷受体拮抗剂的5-氮杂吲唑衍生物
US20220280650A1 (en) Compounds for degrading alpha-synuclein aggregates and uses thereof
CA2983391C (fr) 4-aminopiperidine acylee comme inhibiteurs de serine palmitoyltransferase
CA3218573A1 (fr) Composes pour la degradation d'agregats d'alpha-synucleine et leurs utilisations
IL296602A (en) n-(Heterocyclyl and heterocyclylalkyl)-3-benzylpyridine-2-amine derivatives as sstr4 agonists
CZ2001236A3 (cs) Heterocyklické sloučeniny jako inhibitory rotamasy